ARS Pharmaceuticals

SPRYApproved

San Diego, United StatesFounded 2015ars-pharma.com

ARS Pharmaceuticals is dedicated to transforming the treatment of severe allergic reactions by developing innovative, needle-free therapies. Its flagship product, neffy, represents a significant advancement in epinephrine delivery, offering a portable, easy-to-use alternative to traditional auto-injectors. The company is now commercializing neffy in the US and advancing its pipeline for other mast-cell mediated conditions. Founded in 2015, ARS Pharma is a public company (NASDAQ: SPRY) with a seasoned leadership team experienced in bringing novel therapies to market.

Market Cap

$811.3M

Founded

2015

Focus

Drug DeliverySmall Molecules

SPRY · Stock Price

USD 8.17+4.48 (+121.41%)

Historical price data

AI Company Overview

Technology Platform

Proprietary intranasal delivery platform for needle-free administration of epinephrine and potential other therapies for mast-cell mediated conditions.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
Neffy + Adrenaline	Allergic Reactions	Approved
ARS-1 + Placebo	Urticaria	Phase 2
ARS-1 + Albuterol MDI + Placebo	Asthma	Phase 2
Placebo + 0.5 mg epinephrine + 1 mg epinephrine	Urticaria Chronic	Phase 2
ARS-1 with URTI + ARS-1 without URTI	Upper Respiratory Tract Infection	Phase 1

Funding History

Total raised: $195M

IPO$125MUndisclosedSep 29, 2022

Series B$45MSR OneFeb 15, 2020

Series A$25MSR OneOct 15, 2017

FDA Approved Drugs

NEFFYNDAAug 9, 2024

Opportunities

The primary growth opportunity is capturing significant market share in the large epinephrine auto-injector market by converting needle-averse patients and caregivers.

A major secondary opportunity is label expansion into acute treatment of urticaria flares, which would open a new, sizable patient population and create a novel treatment paradigm.

Risk Factors

Key risks include commercial failure due to slow physician adoption or payer resistance, competition from entrenched auto-injector brands, and potential clinical setbacks in pipeline expansion efforts.

The company's financial sustainability is heavily reliant on the success of a single product launch.

Competitive Landscape

ARS Pharma's main competitors are epinephrine auto-injector manufacturers like Viatris (EpiPen) and Kaléo (Auvi-Q). neffy's key differentiation is its needle-free, nasal spray delivery, which addresses needle-phobia and portability issues. It holds a first-mover advantage in the FDA-approved needle-free epinephrine category.

Publications

Patents

Pipeline

FDA Approvals